Drug intelligence / Profile preview

JBPOS0451

Development stage: Preclinical
Lead developer: Bio-Pharm Solutions
Modality: Small Molecules
Administration: Oral

Overview

JBPOS0451 is a small molecule therapeutic candidate developed by Bio-Pharm Solutions for the treatment of central nervous system (CNS) disorders. It is currently in preclinical development for indications including epilepsy, infantile spasms (IS), and pain management. The compound has been evaluated through the NIH National Institute of Neurological Disorders and Stroke (NINDS) "Red Book" program, which is part of the Anticonvulsant Screening Program (ASP). While the specific molecular target of JBPOS0451 has not been publicly disclosed, Bio-Pharm Solutions focuses on the development of metabotropic glutamate receptor (mGluR) modulators and other small molecules derived from their proprietary CNS-focused chemical library.

Beyond the preview

Go deeper on JBPOS0451.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JBPOS0451.

Explore the full profile